Oracle Predictions Tracker

FDA issues a Complete Response Letter for MDMA-assisted therapy, citing inadequate blinding controls and therapist fidelity data, requiring at least one additional trial before resubmission.

Stanford's DOD-funded ibogaine veteran trial will publicly release preliminary outcomes data by Q3 2026, directly cited in at least one congressional hearing or formal Senate briefing.

A named veteran will deliver live or recorded congressional testimony specifically about personal ibogaine treatment outcomes before September 2026, constituting the highest-profile psychedelic policy moment of the year.

A peer-reviewed meta-analysis formally quantifying blinding failure rates across MDMA-AT randomized controlled trials will be published in a journal with impact factor >5 by Q1 2027.

A major investigative piece exposing financial conflicts of interest between named Republican political figures and venture-backed psychedelic companies will be published by a top-10 U.S. outlet before September 2026.

Psilocybin remains federally Schedule I in the USA through December 31, 2028.

No U.S. state beyond Oregon and Colorado enacts a legal therapeutic psilocybin access framework (not just decriminalization) signed into law before January 1, 2028.

At least three peer-reviewed papers on psychedelic neuroplasticity mechanisms are published in Nature-family or Cell-family journals in calendar year 2026.

At least one Phase 3 psychedelic trial (psilocybin for MDD or a supplemental MDMA-PTSD study) reports a statistically significant primary endpoint result by December 31, 2026.

Psychedelic therapy research provisions are included in the FY2027 NDAA or a VA appropriations bill passed by December 15, 2026.

Mainstream media will materially misrepresent at least one psilocybin RCT finding published in May 2026 within 60 days, with a named researcher publicly issuing a correction request by August 21, 2026.

DEA will submit formal written opposition to any NDAA ibogaine veteran access amendment before the Senate Armed Services Committee markup, citing cardiac safety data and Schedule I diversion risk.

Ibogaine cardiac safety will remain the primary stated regulatory bottleneck blocking IND expansion in the US through June 30, 2027, with no FDA formal guidance issued permitting expanded ibogaine trials without mandatory cardiac monitoring protocols.

The ibogaine visual cortex plasticity finding will be cited by at least 5 peer-reviewed mechanistic studies at independent institutions by May 23, 2027, expanding ibogaine's scientific framing beyond addiction.

A major mainstream outlet (top-50 US or UK publication by traffic) will publish a feature conflating psilocybin cocaine use disorder trial findings with recreational microdosing trends by July 7, 2026, generating at least one named researcher publicly objecting within 14 days of publication.

FDA will issue formal guidance requiring mandatory cardiac monitoring protocols for ibogaine INDs before end of 2026

Veterans will be the named beneficiary population in the majority of psychedelic access bills introduced in US state legislatures in 2026, with ibogaine bills outnumbering psilocybin or MDMA bills

DEA will initiate at least two publicly announced enforcement actions against unlicensed psychedelic clinic operators before end of 2026

No new psychedelic compound will receive FDA Breakthrough Therapy Designation in 2026

At least two US states will enact Right-to-Try or expanded access legislation explicitly naming ibogaine for veteran PTSD or TBI treatment before 2027-07-01

FDA will formally require prospective cardiac monitoring REMS as a non-negotiable precondition for any ibogaine IND approval in veteran-access programs by Q1 2027

The number of identifiable US-based or Mexico/Caribbean-based retreats explicitly marketing to US veterans for ibogaine treatment will be at least 40% higher than current baseline by 2027-05-21

A documented fatality at a US-based or US-citizen-attended gray-market ibogaine retreat will receive national mainstream media coverage and prompt at least one congressional hearing within 12 months

At least one major pharmaceutical company (top-20 by revenue) will announce a psilocybin licensing deal or acquisition of COMPASS Pathways or ATAI Life Sciences by 2027-02-21

At least three NIH R01 or equivalent grant applications explicitly targeting ibogaine's cortical plasticity mechanism in non-addiction CNS indications (amblyopia, stroke, TBI) will be funded within 18 months

Psilocybin will remain Schedule I through end of 2027, as no NDA has been filed and DEA rescheduling requires completion of a formal administrative process that FDA approval would trigger but publication volume cannot accelerate.

At least one major mainstream US news outlet will publish a headline characterizing the cocaine use disorder psilocybin RCT results as evidence that 'psychedelics cure addiction' within 30 days of publication, followed by a correction cycle that complicates congressional messaging.

A psilocybin NDA for treatment-resistant MDD will be filed with the FDA by COMPASS Pathways or a direct competitor by November 2027, citing recent RCT data as supportive evidence alongside existing Phase 3 results.

The ibogaine juvenile plasticity finding will generate at least 3 NIH R01 grant awards (not merely applications) specifically targeting critical period plasticity mechanisms within 18 months of May 2026.

Ibogaine will remain Schedule I through December 31, 2029, with DEA's 8-factor analysis citing cardiac liability as sufficient procedural basis to deny rescheduling despite active IND filings and veteran advocacy pressure

CMPS (Compass Pathways) will not recover above $12.50 by August 19, 2026, confirming that publication volume is not an investable catalyst and only binary FDA events or M&A signals move institutional psychedelic capital

The psilocybin cocaine RCT will be significantly misrepresented in at least three major mainstream media outlets within 72 hours of publication, and a researcher-led public correction effort will itself generate coverage framing psychedelic science as prone to hype cycles

FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND approval proceeds, by Q1 2027.

Psilocybin cocaine RCT extinction-without-relapse-prevention finding will generate 3+ follow-up mechanistic studies within 18 months investigating default mode network suppression during extinction learning.

Senate Veterans Affairs Committee will hold ibogaine-specific hearings with Stanford researchers testifying before September 2026.

A major investigative piece linking ibogaine cardiac deaths specifically to veteran treatment programs will publish in a top-tier outlet before August 2026.

CMPS will outperform MMED by at least 15% on a 6-month basis as psilocybin depression RCT data is absorbed by institutional allocators.

Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT data.

California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psychedelic therapy market.

No psychedelic substance (psilocybin, MDMA, ibogaine, ketamine analogues, or LSD) will be federally rescheduled from Schedule I in the United States before January 1, 2028.

Psychedelic biotech sector equities (as measured by a basket of publicly traded psychedelic companies) will show negative or flat returns through Q4 2026 absent a concrete FDA approval or positive advisory committee vote for a psychedelic compound.

At least 5 NIH-funded mechanistic follow-up studies on ibogaine's neural plasticity mechanism will be awarded within 2 years, with at least one study explicitly targeting non-hallucinogenic analogue development.

FDA will issue formal written cardiac safety guidance or a mandatory cardiac screening requirement specifically for ibogaine INDs before June 2027, materially delaying at least one active veteran access program.

The cocaine-psilocybin 'extinction without relapse prevention' finding will be cited by name in at least 3 pieces of formal anti-psychedelic congressional testimony or submitted written statements within 12 months of publication.

Mandatory federal cardiac safety protocols for ibogaine will be required before any regulated U.S. therapeutic access program launches, causing delays of at least 18 months beyond currently projected timelines.

FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND expansion, delaying veteran-focused trials by 12-18 months

At least three non-hallucinogenic structural ibogaine analogues will enter preclinical development within 36 months, driven by neuroplasticity mechanism findings

A formal congressional study commission on psychedelic medicine will be established via NDAA or standalone legislation before end of 2026, but no scheduling or prescribing legislation will pass before 2028

At least two sponsors will submit accelerated approval pathway applications to FDA for psilocybin-based therapies by November 2027

Ibogaine remains Schedule I through 2028 with no rescheduling petition advancing past initial DEA review

The dissociation between extinction and relapse-prevention in the cocaine psilocybin RCT becomes a primary mechanistic research focus, generating an identifiable sub-literature of at least 10 peer-reviewed papers on consolidation vs. extinction within 24 months of publication

FDA publishes formal guidance requiring cardiac monitoring infrastructure as prerequisite for ibogaine IND expansion or rescheduling petition before end of 2026

At least $50M in new NIH and DARPA grant awards targeting ibogaine analog development and neuroplasticity mechanism characterization is announced within 18 months of 2026-05-15

Formal federal regulatory or legislative language codifying hospital-grade cardiac monitoring as a prerequisite for any ibogaine access pathway is published before 2026-08-13

State-level psychedelic access legislation remains the primary U.S. policy vector through end of 2027, with at least one state (California most likely) enacting a regulated access framework ahead of any federal scheduling or approval action.

Ibogaine neuroplasticity mechanism generates at least 5 major peer-reviewed mechanistic studies AND 2 dedicated research consortia by end of 2027, independent of clinical regulatory outcomes.

Ibogaine cardiac safety concerns produce a formal regulatory OR legislative response — FDA Safety Communication or congressional cardiac monitoring mandate — by end of 2026.

FDA issues a formal Drug Safety Communication on ibogaine cardiac risk (QT prolongation, ventricular arrhythmia) by Q4 2026.

Ibogaine will not achieve federal NDA approval or Schedule I rescheduling before January 1, 2028.

No federal psychedelic scheduling reform legislation will reach a floor vote in either the House or Senate before November 2028.

DEA will formally oppose any rescheduling petition for ibogaine before 2028, citing cardiac liability literature as sufficient scientific basis for continued Schedule I classification.

FDA will issue a formal safety communication or guidance document specifically addressing ibogaine cardiac risk before end of 2026.

A noribogaine or ibogaine-analogue biotech will announce a financing round above $30M (Series A or B) before end of Q1 2027, with communications explicitly referencing ibogaine cardiac liability as validating the safer-analogue development thesis.

The psilocybin cocaine RCT will be widely misreported as a 'cure for addiction' in at least 3 major mainstream outlets, followed by a published correction or debunking piece within 60 days of initial coverage.

At least one U.S. Congressional committee will hold a public hearing specifically addressing FDA policy on ibogaine (including access, scheduling, or clinical trial pathways) before March 31, 2027.

At least one pre-registered multi-site replication trial of psilocybin's extinction-without-relapse-prevention mechanism in substance use disorder will be launched (registered on ClinicalTrials.gov or equivalent) before June 30, 2027.

FDA will issue a formal Safety Communication specifically on ibogaine-associated cardiac risks (QT prolongation/arrhythmia) before December 31, 2026.

FDA will issue a formal Safety Communication on ibogaine cardiac risks before August 10, 2026, and this will create a measurable regulatory divergence in IND approval timelines between natural ibogaine and synthetic analogue (e.g., tabernanthalog, TBG) applications.

The extinction-without-relapse dissociation observed in psilocybin-cocaine studies will generate at least 3 competing mechanistic hypotheses in peer-reviewed literature within 12 months.

At least 4 new U.S. state bills legalizing or decriminalizing psychedelic therapy will pass by 2026-11-07, while no federal psychedelic therapy legislation advances past committee.

Veteran-led psychedelic retreat networks will serve over 5,000 veterans in informal settings by end of 2026.

FDA will issue a formal safety communication specifically on ibogaine cardiac risks by 2027-02-11.

Ibogaine will face a formal FDA or DEA safety communication within 12 months (by 2026-08-09) that materially constrains any U.S. access expansion before 2028.

At least one U.S. state (most likely California) will operationalize a regulated psilocybin access framework with licensed facilitators before any federal scheduling change, creating a de facto two-tier system.

FDA will require at least one independent replication of psilocybin RCT data for cocaine use disorder before considering it label-worthy, making 2029 the earliest realistic approval date for that indication.

Any viable ibogaine NDA pathway will formally require a mandatory cardiac monitoring protocol, making 2028 the earliest realistic federal approval date.

FDA will issue a formal ibogaine safety communication or guidance document citing cardiac risk before issuing any IND pathway expansion, effectively adding 12-18 months to regulatory timeline.

California will enact legislation establishing a regulated psilocybin therapy framework with a licensed facilitator model before end of 2026.

A veteran death in an unregulated foreign ibogaine setting, with documented prior VA system contact, will trigger a formal U.S. Congressional hearing on ibogaine safety and access before end of 2026.

Ibogaine cardiac safety will become a formal regulatory bottleneck — via FDA IND hold letters, draft guidance, or DEA opposition — before December 31, 2026, forcing sponsors toward analog development or stricter protocol constraints.

FDA will issue a formal Safety Communication or draft guidance specifically addressing ibogaine cardiac monitoring requirements before December 31, 2026.

At least two pharmaceutical sponsors will file new INDs or major trial amendments targeting psilocybin for cocaine use disorder before December 31, 2026.

DEA will formally oppose or delay any pending ibogaine rescheduling petition before December 31, 2026, citing cardiovascular adverse event literature published in 2026.

Psilocybin for cocaine use disorder will emerge as a named pipeline indication with at least two new IND filings or primary-endpoint trial amendments documented before August 7, 2026.

Federal rescheduling of any classical psychedelic will not occur before 2028, due to DEA independent scheduling process adding 18-24 months beyond any FDA action

DEA will initiate formal scheduling review proceedings for psilocybin within 6 months of any FDA approval recommendation, extending access timelines by minimum 18 months

FDA will issue a formal ibogaine cardiac safety guidance document requiring mandatory QT monitoring protocols before any IND expansion, slowing veteran access trials by 12-18 months

A documented serious adverse event at a commercial psychedelic retreat will receive major national media coverage before end of 2026, triggering emergency state-level regulatory review in Oregon or Colorado

Ibogaine cardiac safety documentation will drive regulatory and investment bifurcation between natural ibogaine (restricted, mandatory monitoring) and synthetic analogs (accelerated development), with distinct treatment pathways formalized in FDA guidance or legislation by end of 2027

Federal psilocybin scheduling reform will not receive a floor vote in the 119th Congress (ending January 3, 2027).

No federal rescheduling of any classical psychedelic — psilocybin, MDMA, LSD, DMT — will occur before 2028.

Ibogaine cardiac safety will remain the primary regulatory gating factor for all FDA and Congressional ibogaine progress through at least mid-2027.

FDA will issue a formal clinical hold or safety guidance on at least one ibogaine IND citing QT prolongation before end of 2026.

FDA will not publish a formal guidance document on SSRI-psychedelic washout protocols before November 2027.

Psychedelic-assisted therapy will be standard in psychiatric training programs by January 2028.

Microdosing will see at least 5 new FDA-approved IND applications filed before December 2026.

Psychedelic field will achieve formal bipartisan Congressional recognition before end of 2026.

At least one psychedelic compound — most likely COMPASS Pathways COMP360 — will receive FDA approval or formal approval recommendation before end of 2027.

Psychedelic biotech sector will trade higher 6 months post-EO (October 2026) versus pre-EO (April 17, 2026).

Trump EO Right to Try pathway will produce at least one operational psychedelic patient access program before January 2027.

UC system (UCSF, UCLA, UCSD) will publish statistically significant psilocybin results in a non-psychiatric indication before December 2027.

DEA will formally initiate rescheduling review for at least one psychedelic compound before April 2027.

Major pharma company will announce licensing, acquisition or partnership with psychedelic biotech before January 2027.

No standalone federal psychedelic scheduling bill will pass both chambers before the 2026 midterms.

At least two additional U.S. states will formally introduce legislation establishing veteran-specific psychedelic therapy access programs in calendar year 2026.

DEA will submit formal written opposition to any NDAA provision creating ibogaine veteran access that bypasses Schedule I review, before December 31 2026.

FDA will issue formal written guidance requiring mandatory cardiac screening (ECG, QTc baseline) for any ibogaine IND submitted or amended in 2026.

By November 2026, at least one major ibogaine clinical-stage company or academic program will publicly announce a pivot toward non-cardiotoxic ibogaine analogs (e.g., oxa-noribogaine) as their primary development candidate.

FDA will issue formal guidance specifically addressing cardiac monitoring requirements for ibogaine and ibogaine analog trials by Q2 2027.

A serious adverse event at an unregulated U.S. ketamine or psychedelic clinic will be cited in congressional hearing testimony or trigger a formal federal investigation within 12 months of today.

FDA will issue formal guidance on QT monitoring requirements for ibogaine by mid-2027, and this guidance will be cited as a primary reason for delay in at least one IND progress report filed before December 2027.

At least three published clinical trial protocol amendments for ongoing psilocybin or MDMA trials will cite SSRI/fluoxetine interaction data as justification for modified washout criteria by Q3 2026.

SSRI washout protocols will be formally required (via FDA mandate or sponsor-initiated amendments across at least five active trials) for MDMA and psilocybin INDs by August 2026, causing measurable enrollment delays at multiple sites.

Any federal ibogaine access legislation that passes both chambers will include mandatory cardiac screening as a statutory floor requirement.

MMED (Mind Medicine) share price will remain below its Q1 2026 high through September 30, 2026, absent a confirmed FDA catalyst event.

The psychedelic biotech sector (as proxied by PSYK ETF or equivalent index) will show no positive return from May 2026 levels through June 2, 2026, absent a confirmed FDA approval or Phase 3 trial success announcement.

FDA will issue formal guidance requiring cardiac screening protocols as a precondition for ibogaine IND approval by Q1 2027.

Glutamatergic mPFC modulation will be cited as the primary mechanistic hypothesis for ibogaine-class therapeutic effects in the majority of new ibogaine/noribogaine preclinical publications by end of 2028.

Cardiac screening will be included as a mandatory requirement in at least one enacted or advanced federal ibogaine access bill or FDA guidance document by August 2026.

No psychedelic compound will receive FDA approval or be federally rescheduled before 2026-12-31.

Psychedelic biotech sector aggregate market cap will not recover to 2024 highs before 2026-09-30, absent an FDA approval or clear NDA acceptance for a psychedelic compound.

FDA will issue formal written guidance requiring cardiac monitoring protocols (including QT-interval surveillance) as a prerequisite for any ibogaine or ibogaine-analog IND submission, before 2027-01-15.

Psychedelic biotech equities will remain below 2024 high-water marks through 2026-09-30, with no sector-wide recovery absent a positive FDA binary event.

Ibogaine cardiac safety literature will constitute a recognized regulatory signal sufficient to require mandatory cardiac monitoring protocols in any new IND submission for ibogaine or close analogs, delaying direct ibogaine clinical development timelines materially into 2027.

FDA will issue formal guidance requiring mandatory cardiac screening protocols (ECG, QTc thresholds) for any ibogaine IND by Q3 2026, effectively gatekeeping clinical access without blocking analog development.

At least two Phase 3 psychedelic trials will formally adopt standardized fluoxetine washout protocols (documented in trial registry or protocol amendment) by Q4 2026.

Oxa-noribogaine developers will achieve a sustained public market or disclosed private valuation premium of 40%+ over comparable raw ibogaine-focused companies within 12 months of 2026-05-01.

FDA will formally request endpoint renegotiation or place a clinical hold on at least one active psilocybin or ibogaine addiction trial citing mismatch between extinction-enhancement mechanism and relapse-prevention primary endpoint by Q2 2027.

Fluoxetine washout standardization will be documented as adopted protocol practice across at least two Phase 3 psychedelic trials by 2026-07-30.

DEA maintains Schedule I status for psilocybin and MDMA through October 2026 with no approved rescheduling petition

MAPS or Compass Pathways publishes Phase 3 psilocybin trial enrollment or safety data update

A bipartisan psychedelic research bill is introduced in the U.S. Congress

MAPS or Compass Pathways publicly announces Phase 3 psilocybin efficacy data or a formal FDA pre-approval meeting

A U.S. federal or state bill specifically addressing indigenous ceremonial plant medicine access or sovereignty is formally introduced

At least one U.S. state legislature passes a psychedelic decriminalization or regulated therapeutic access bill

A U.S. insurer, CMS, or federal agency issues formal guidance or announces a pilot program for psychedelic-assisted therapy reimbursement

No ibogaine product achieves FDA approval before 2030

DEA completes its Schedule I review process for psychedelics without rescheduling any substance to Schedule II or III before 2028-01-01

No federal ibogaine approval pathway is established before 2029

At least three additional U.S. states pass veteran-specific ibogaine access legislation by end of 2027

Fluoxetine-psychedelic drug-drug interaction research generates at least five independent replication studies published in peer-reviewed journals by 2028-04-29

Fluoxetine-psychedelic drug-drug interaction becomes a required screening criterion in federally funded psychedelic trials by 2028-04-29

FDA issues formal protocol amendment guidance affecting active psychedelic clinical trials based on fluoxetine-psychedelic interaction data by Q2 2027

No psychedelic substance is rescheduled from Schedule I to Schedule II or III in the United States before January 1, 2029

Ibogaine's cardiac safety profile causes at least one major clinical trial sponsor to publicly pause or redesign an ibogaine IND before December 31, 2027

Oxa-noribogaine enters a human Phase 1 clinical trial before October 31, 2027

CMPS (Compass Pathways) closes below $7.00 on at least one trading day before June 30, 2026

FDA issues a formal guidance document specifically addressing psychedelic-SSRI pharmacodynamic interactions and washout requirements for psychedelic clinical trials before December 31, 2027

Ibogaine will become the central contested exhibit in the 2026-2027 psychedelic safety culture war, simultaneously weaponized by pro-regulation and anti-prohibition advocates

Ibogaine cardiac safety concerns will materially slow or condition U.S. regulatory pathways, requiring mandatory cardiac monitoring protocols that will significantly increase deployment costs and complexity

Psilocybin will be the first classic psychedelic to receive FDA NDA acceptance for review for treatment-resistant MDD, with acceptance by Q2 2028

Fluoxetine-psychedelic interaction data will be incorporated into FDA guidance requiring standardized SSRI washout criteria for psychedelic NDA submissions within 24 months